Latest Oncology News

cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection

cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection

September 19th 2021

Antonia DePace

Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection.

Balstilimab plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

Balstilimab plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

September 19th 2021

Kyle Doherty

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.

Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer, But Nivolumab/Ipilimumab Arm Misses Mark

Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer, But Nivolumab/Ipilimumab Arm Misses Mark

September 19th 2021

Gina Mauro

The frontline combination of nivolumab and chemotherapy upheld its improvement in progression-free and overall survival vs chemotherapy alone with longer follow-up of patients with advanced gastric, gastroesophageal junction, or esophageal cancer, according to data from the phase 3 CheckMate-649 trial.

Tisotumab Vedotin Plus Frontline Carboplatin and Second-/Third-Line Pembrolizumab Demonstrates Notable Activity in Recurrent/Metastatic Cervical Cancer

Tisotumab Vedotin Plus Frontline Carboplatin and Second-/Third-Line Pembrolizumab Demonstrates Notable Activity in Recurrent/Metastatic Cervical Cancer

September 19th 2021

Caroline Seymour

Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

September 19th 2021

Conor Killmurray

Adagrasib alone or in combination with cetuximab elicited encouraging antitumor activity and safety in heavily pretreated patients with KRAS G12C–mutant colorectal cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.

Latest Oncology Videos

All Oncology News

Dr. Blakely on the Design of a Trial Evaluating Osimertinib in Resectable EGFR-Mutant NSCLC

September 15th 2021

Collin Blakely MD, PhD

Collin Blakely MD, PhD, discusses the design of an ongoing phase 2 trial examining osimertinib in resectable EGFR-mutant non–small cell lung cancer.

Dr. Shah on the Current State of Cellular Therapy in Multiple Myeloma

September 15th 2021

Nina Shah, MD

Nina Shah, MD, discusses the current state of cellular therapy in multiple myeloma.

FDA Approves Mobocertinib for EGFR Exon 20 Insertion+ NSCLC

September 15th 2021

Kristi Rosa

The FDA has approved mobocertinib for the treatment of adult patients with locally advanced or metastatic non–small cell lung cancer with EGFR exon 20 insertion mutations as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Acalabrutinib Demonstrates Improved Tolerability, Similar Efficacy to Ibrutinib in CLL

September 15th 2021

Maggie Tibbitt

John C. Byrd, MD, , discusses key findings from ELEVATE-RR, differences between acalabrutinib and ibrutinib, and future directions with the second-generation inhibitor.

Dr. Pecot on Selecting Between Available Targeted Therapies in NSCLC

September 15th 2021

Chad Pecot, MD

Chad V. Pecot, MD, discusses selecting between available targeted therapies in RET-, KRAS-, and MET exon 14 skipping–mutant non–small cell lung cancer.

Dr. Kahl on Patient Selection for Intensive Vs Non-Intensive Treatment in MCL

September 15th 2021

Brad S. Kahl, MD

Brad S. Kahl, MD, discusses patient selection for intensive vs non-intensive treatment strategies in mantle cell lymphoma.

Dr. Shah on Unmet Needs With CAR T-Cell Therapy in Multiple Myeloma

September 15th 2021

Nina Shah, MD

Nina Shah, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Tisotumab Vedotin–Based Combos Demonstrate Antitumor Activity in Recurrent/Metastatic Cervical Cancer

September 15th 2021

Jessica Hergert

Treatment with the antibody-drug conjugate tisotumab vedotin in combination with bevacizumab, pembrolizumab, or carboplatin was tolerable and elicited encouraging preliminary antitumor activity in patients with recurrent or metastatic cervical cancer.

CDK Inhibition May Overcome Mechanisms of Olaparib Resistance in Prostate Cancer

September 15th 2021

Jason M. Broderick

By studying olaparib-sensitive and -resistant cell lines, researchers were able to gather insights regarding PARP inhibitor treatment and resistance mechanisms, including the use of CDK inhibition as a potential means of overcoming PARP inhibitor resistance in prostate cancer.

Cancer Treatment Centers of America Partners with MedAllies to Innovate on Best-in-Class Patient Notifications for CMS and Provider Network

September 15th 2021

CTCA leverages new CMS Conditions of Participation notification requirements as opportunity for innovation

Promising Results Push Nivolumab/Chemotherapy Forward in Gastric Cancer

September 15th 2021

Kyle Doherty

Jaffer A. Ajani, MD, unpacks the performance of nivolumab in combination with chemotherapy in some subgroups of gastric cancer.

Initial Guideline Development Showcases Future Directions in Ultra-Rare Sarcoma Subtype

September 15th 2021

Jessica Hergert

As part of a global consensus meeting, experts from several disciplines convened to define evidence-based guidelines for the treatment of patients with primary and metastatic epithelioid hemangioendothelioma with locoregional and systemic therapies, as well as palliative care.

Optimal Management of ILD in Patients With Breast Cancer

September 15th 2021

Mark Pegram, MD, Stanford Women's Cancer Center

Shared insight on the optimal management of patients who develop interstitial lung disease while receiving therapy for breast cancer.

FDA Approves Zanubrutinib for Relapsed or Refractory Marginal Zone Lymphoma

September 15th 2021

Kristi Rosa

The FDA has granted an accelerated approval to zanubrutinib for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least 1 anti–CD20-based regimen.

Breast Cancer Management: Monitoring Patients for ILD

September 15th 2021

Mark Pegram, MD, Stanford Women's Cancer Center

In light of breast cancer therapies with the potential to cause interstitial lung disease, experts consider important patient risk factors and best monitoring practices.

See All News